← Back to Search

GLP-1 RA

Semaglutide for Obesity

Phase 4
Waitlist Available
Research Sponsored by San Francisco Veterans Affairs Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients ≥ 18 years old with a BMI ≥ 27 kg/m2 who have paroxysmal AF with a ≥ 10% burden on ambulatory monitoring or a previous electrical cardioversion or early persistent AF (≥ 7 days, < 3 months) who are willing to attempt rhythm control.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights

Study Summary

This trial will test whether semaglutide, a drug currently approved for weight loss, can also help reduce the burden of atrial fibrillation (AF). The study will last 52 weeks and will compare semaglutide to placebo. The primary outcome will be the change in AF burden for 2 weeks at the end of the study.

Eligible Conditions
  • Obesity
  • Atrial Fibrillation

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Atrial fibrillation burden
Secondary outcome measures
Adherence and Adverse Events
Blood pressure
Change in AF burden for four weeks
+10 more

Side effects data

From 2020 Phase 4 trial • 104 Patients • NCT04189848
21%
Nausea
12%
Decreased Appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Overall Study

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SemaglutideExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
FDA approved

Find a Location

Who is running the clinical trial?

San Francisco Veterans Affairs Medical CenterLead Sponsor
48 Previous Clinical Trials
210,631 Total Patients Enrolled
1 Trials studying Obesity
20 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
Idaho
How old are they?
18 - 65
65+
What site did they apply to?
Veterans Affairs Medical Center San Francisco
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Most responsive sites:
  1. Veterans Affairs Medical Center San Francisco: < 48 hours
Average response time
  • < 2 Days
Typically responds via
Phone Call
Recent research and studies
clinicaltrials.govStudy
Semaglutide to Reduce Atrial Fibrillation Burden
Adam Oesterle 2023. "Semaglutide to Reduce Atrial Fibrillation Burden". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05209165.
~88 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top